Prime-boost immunization strategies against Chikungunya virus

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Chikungunya virus (CHIKV) is a reemerging mosquito-borne alphavirus causing significant human arthralgia.
• There is currently no licensed vaccine to prevent CHIKV infection, highlighting an urgent need for effective preventative measures.

Purpose of the Study:

• To develop and test novel DNA replicon and protein CHIKV vaccine candidates.
• To evaluate homologous and heterologous prime-boost immunization strategies for CHIKV vaccine candidates.
• To assess the immunogenicity and efficacy of these strategies in a mouse model.

Main Methods:

• Development and testing of DNA replicon and protein CHIKV vaccine candidates.
• Homologous and heterologous prime-boost immunization in a mouse model.
• Evaluation of antigen-specific immune responses, antibody epitope mapping, and protection against CHIKV challenge.

Main Results:

• DNA replicon and protein CHIKV vaccine candidates demonstrated potent immunogenicity.
• Prime-boost strategies, particularly those combining different vaccine types, significantly enhanced humoral and cellular immune responses.
• Most vaccine modalities provided complete protection against wild-type CHIKV, though some regimens showed potential for enhanced inflammation.

Conclusions:

• Novel DNA replicon and protein CHIKV vaccine candidates are effective, especially when employed in prime-boost strategies.
• Combined immunization approaches significantly boost immune responses, crucial for developing an efficacious CHIKV vaccine.
• Further preclinical and clinical evaluation is warranted to optimize CHIKV vaccine design and guide future studies.